Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 18/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 18/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21620995 | 0.95 | PDCD1 (0.47) | PDCD1CD274HDAC3HDAC1HDAC6 | |
| SCHEMBL29716127 | 0.95 | PDCD1 (0.47) | PDCD1CD274HDAC3HDAC1HDAC6 | |
| SCHEMBL21451792 | 0.94 | PDCD1 (0.45) | PDCD1CD274HDAC3HDAC1HDAC6 | |
| SCHEMBL21621008 | 0.90 | PDCD1 (0.43) | PDCD1CD274HDAC3HDAC1HDAC6 | |
| SCHEMBL29716258 | 0.90 | PDCD1 (0.43) | PDCD1CD274HDAC3HDAC1HDAC6 | |
| SCHEMBL29716182 | 0.90 | PDCD1 (0.42) | PDCD1CD274 | |
| SCHEMBL21621006 | 0.90 | PDCD1 (0.42) | PDCD1CD274 | |
| SCHEMBL22966491 | 0.90 | PDCD1 (0.42) | PDCD1CD274HDAC3HDAC1HDAC6 | |
| SCHEMBL21621007 | 0.89 | PDCD1 (0.45) | PDCD1CD274 | |
| SCHEMBL29716196 | 0.89 | PDCD1 (0.45) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119411-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20220119411-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| WO-2020011243-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020011243-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119411-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | IL2, IL5, TSLP | PDCD1 409/4885CD274 148/4885HDAC3 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.